FY2026 Earnings Forecast for OVID Issued By HC Wainwright

Ovid Therapeutics Inc. (NASDAQ:OVID) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for Ovid Therapeutics in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.60) for the year. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share.

A number of other brokerages also recently commented on OVID. BTIG Research decreased their target price on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Monday. Wedbush reissued an “outperform” rating and set a $3.00 price objective (down from $4.00) on shares of Ovid Therapeutics in a research report on Wednesday, March 12th. Finally, Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 target price for the company in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $3.03.

Ovid Therapeutics Trading Down 3.2 %

OVID opened at $0.43 on Tuesday. The firm has a market capitalization of $30.58 million, a price-to-earnings ratio of -0.92 and a beta of 0.29. Ovid Therapeutics has a one year low of $0.42 and a one year high of $3.45. The business has a 50 day simple moving average of $0.59 and a two-hundred day simple moving average of $0.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.19 million.

Hedge Funds Weigh In On Ovid Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Ovid Therapeutics by 1,907.4% in the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after acquiring an additional 47,723 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Ovid Therapeutics by 4,128.7% in the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock worth $260,000 after purchasing an additional 215,189 shares during the period. Verition Fund Management LLC bought a new position in shares of Ovid Therapeutics during the third quarter valued at approximately $88,000. XTX Topco Ltd increased its stake in shares of Ovid Therapeutics by 46.2% during the third quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after purchasing an additional 12,076 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Ovid Therapeutics by 311.2% during the third quarter. Barclays PLC now owns 84,175 shares of the company’s stock valued at $98,000 after purchasing an additional 63,702 shares during the last quarter. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.